Details of the Drug

General Information of Drug (ID: DMG65WH)

Drug Name
Ficlatuzumab
Synonyms AV-299
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 2 [1]
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Pancreatic cancer 2C10 Phase 2 [2]
Squamous cell carcinoma 2B60-2D01 Phase 2 [2]
Acute myeloid leukaemia 2A60 Phase 1 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
77E89833TG
DrugBank ID
DB11680
TTD ID
D03UBW
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatocyte growth factor (HGF) TT4V2JM HGF_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Multiple myeloma
ICD Disease Classification 2A83
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepatocyte growth factor (HGF) DTT HGF 4.90E-01 0.13 2.73
Hepatocyte growth factor (HGF) DTT HGF 1.98E-07 1.58 2.92
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)